Dendritic cell immunotherapy and topotecan-based metronomic chemotherapy in ovarian cancer - a case study and literature review

Advanced ovarian cancer is associated with an unsatisfactory prognosis. Systemic treatment toxicities adversely affect patient quality of life. Therefore, new, better therapies are needed. We present a case of a patient treated for recurrent ovarian cancer with a sequence of experimental cellular immunotherapy and chemotherapy in both classical and metronomic dosing with satisfactory results. A brief literature review on the subject of metronomic chemotherapy and immunotherapy in ovarian cancer is also provided. The addition of a dendritic vaccine to standard chemotherapy may be a valuable therapeutic option in the group of patients with platinum-sensitive recurrent ovarian cancer. Metronomic chemotherapy is not adequately researched in this setting although it appears to be a noteworthy alternative to classically dosed chemotherapy.